Lion's Mane: my dreams changed, and that proves nothing

I have been taking Lion's Mane for a few months. The effect I was not expecting, and by far the clearest one, concerns my dreams.

They have become detailed to the point of being readable. In one of them I was in class, leaning over a classmate's screen, reading the text displayed on it. Not the blurred impression of text: the text. The transitions hold together too, where a dream normally jumps from one setting to another with no logic to it.

So there it is. One person, no control group, no measurement. It proves nothing, and that is what makes the case worth writing about: almost everything published on this mushroom rests on that kind of report, without ever saying so.

What a personal observation is worth, and what it is not

Several compounds started together. I began a batch of new supplements in the same period. Nothing in that protocol allows the whole of the effect to be pinned on this one.

One element cuts the other way, and I mention it out of honesty rather than as a defence: I was not looking for this effect. I had read up on the cognitive side, and had no idea this mushroom carried a reputation about dreams. Expectation therefore drops out on that specific point. What remains missing is a control group and a measurement, so the honest sentence is this one: something changed, and nobody can say whether it is entirely the mushroom. What is left is to look at what has been measured elsewhere.

The whole clinical literature fits in five trials

A systematic review published in 2025 gathered what exists on Lion's Mane. The count speaks for itself: 5 randomised trials, 3 pilot trials, and 15 laboratory studies.

For a product sold in every shop and presented as a cognitive enhancer, that is thin. It does not mean it does not work. It means nobody can assert that it does yet, and that the articles asserting it rest on nothing more than testimonials.

What those trials found

The most cited one is Japanese and dates from 2009: 30 people aged 50 to 80 with mild cognitive impairment, 3 g per day of dried powder for 16 weeks, against placebo, double blind. Cognitive scores in the treated group rise at weeks 8, 12 and 16.

Then comes the detail almost nobody repeats: four weeks after intake stopped, the scores had significantly dropped again. The benefit did not hold on its own.

The only trial run on people like me is a 2023 pilot: 41 healthy adults aged 18 to 45, 1.8 g per day. One hour after a single dose, participants are faster on the Stroop task, which measures the ability to ignore interfering information. At 28 days the reduction in subjective stress does not reach significance, and the authors also report null and a few negative findings.

On sleep, the closest thing to my own observation is a 2026 preprint: 109 adults aged 40 to 75, 2 g per day for eight weeks, with improvements in subjective sleep quality and in feeling rested on waking. A preprint has not yet been peer reviewed, and sleep is not dreaming.

The time I doubled the dose

I take 1 g per day. One evening, out of curiosity, I went up to 2 g. The night lasted nine hours and I woke up tired, with the feeling of having done nothing but dream.

The explanation I give myself fits in one line: according to my own tracking, I already get plenty of REM sleep and little deep sleep, so pushing REM further pushes in the direction I need least. No human trial measures this mushroom's effect on sleep stages: that is a hypothesis, nothing more. The fact itself holds: doubling did not improve the night, it spoiled it.

That gram does not compare with the amounts used in trials either, which run from 1.8 to 3 g of dried powder. Between a powder and a concentrated extract, the same number covers very different things.

The gap between the petri dish and you

The mechanism is why this mushroom attracts so much attention. Two families of compounds, hericenones and erinacines, stimulate the production of nerve growth factors, and their small molecular size is said to let them cross the barrier that protects the brain.

A systematic review devoted to erinacines sorted the evidence in 2025. The picture is encouraging: antioxidant and anti-inflammatory effects, neurogenesis, improved cognitive behaviour. The title states the frame, and that is the whole point: preclinical models. Cells and rodents.

That is where my personal bet sits, and I would rather label it as one. At 19 I am not taking this for the short term: what appeals to me is the idea of a growth factor maintaining connections while the brain is still finishing its wiring. That is a hypothesis built on cells and rodents.

The 2009 result tempers it: an effect that fades four weeks after stopping looks more like support than like construction. That result deserves its own limit, though. It was obtained in people aged 50 to 80 whose functions were declining, and a score falling back in them does not measure what stays learned in someone whose functions are not declining.

The question therefore stays open in both directions: no young brain has been tested on this point.

What your bottle does not say

The two families of compounds are not found in the same place. Hericenones are extracted from the fruiting body, meaning the visible mushroom, while erinacines are mostly isolated from the mycelium, the network of filaments growing through the substrate.

The consequence is direct. The most cited human trials used fruiting body powder; the most enthusiastic preclinical literature covers mycelial erinacines. Two products labelled «Lion's Mane» can therefore point to two different bodies of evidence.

The omega 3 pairing

The combination circulates widely, and the argument works on paper: omega 3s form part of the structure of cell membranes, and DHA is especially high in the brain. Material on one side, growth signal on the other. Each brick has its own literature; the combination itself has not been tested in any trial I could find. Nothing forbids taking both, and I do, but it is a line of reasoning, not a result.

What this article does not say

• That Lion's Mane causes dreams. No trial has measured it, and one isolated case is not data, least of all when several compounds started the same month.
• That the existing trials are solid. Thirty people, forty one people, pilots. These are signals, not conclusions.
• That it will work for you. The most favourable trial involved people aged 50 to 80 whose functions were declining.
• That I am neutral. This is the supplement that surprised me most, which is exactly why I wrote the second section.

« Two true things placed end to end still do not make a proof. »

What Helix does

This case is exactly the one Helix exists to settle in you rather than in an article. You declare the compound, the dose, the form, the part used and the timing; the engine ties what you observe to your markers over time.

For Lion's Mane the displayed evidence level is low, and it will stay low until the literature moves. That is more useful than a list of benefits, and it is the only way to find out whether those dreams are down to the mushroom or to the person having them.